FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 349:2479-2480 December 25, 2003 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Tian, E. PubMed Citation

Multiple myeloma is a cancer in which immunoglobulin-producing plasma cells undergo clonal expansion. Its characteristic feature is the monoclonal, or M, spike, usually detectable in serum or urine by protein electrophoresis. Malignant plasma cells have complex chromosomal rearrangements, leading in many cases to the aberrant activation of gene expression. Some of these activated genes encode secreted factors that can modify the microenvironment of the tumor in a manner that favors its growth or promotes its ability to cause lesions in surrounding tissues. The mechanism of bone destruction, a feature of multiple myeloma, is the focus of the article by Tian . . . [Full Text of this Article]

Source Information

From the Department of Molecular and Human Genetics, Baylor College of Medicine, Houston.

This article has been cited by other articles:

• Ruggiero, S.L., Drew, S.J. (2007). Osteonecrosis of the Jaws and Bisphosphonate Therapy. JDR 86: 1013-1021 [Abstract] [Full Text]  
• Halfdanarson, T. R., Hogan, W. J., Moynihan, T. J. (2006). Oncologic Emergencies: Diagnosis and Treatment. Mayo Clin. Proc. 81: 835-848 [Abstract] [Full Text]  
• Mehrotra, B., Ruggiero, S. (2006). Bisphosphonate Complications Including Osteonecrosis of the Jaw. ASH Education Book 2006: 356-360 [Abstract] [Full Text]  
• Meyer, M. A., Hofbauer, L. C., Neubauer, A., Schoppet, M., Lu, C. M., Walker, R. C., Barlogie, B., Shaughnessy, J. Jr. (2004). DKK1 in Multiple Myeloma. NEJM 350: 1464-1466 [Full Text]